Do analysts rate RYM or ADIL?

Adial Pharmaceuticals has a consensus target price of $15.63, indicating a potential upside of 286.76%. Given Adial Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Adial Pharmaceuticals is more favorable than RYTHM. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RYTHM 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Adial Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Does the media prefer RYM or ADIL?

In the previous week, Adial Pharmaceuticals had 1 more articles in the media than RYTHM. MarketBeat recorded 4 mentions for Adial Pharmaceuticals and 3 mentions for RYTHM. Adial Pharmaceuticals' average media sentiment score of 0.00 beat RYTHM's score of -0.24 indicating that Adial Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment RYTHM 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Adial Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, ADIL or GRCE?

Grace Therapeutics is trading at a lower price-to-earnings ratio than Adial Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adial Pharmaceuticals N/A N/A -$7.98M -$14.73 N/A Grace Therapeutics N/A N/A -$7.79M -$1.18 N/A

Is ADIL or GRCE more profitable?

Grace Therapeutics' return on equity of -36.11% beat Adial Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Adial Pharmaceuticals N/A -203.87% -512.41% Grace Therapeutics N/A -36.11% -34.39%

Does the media refer more to ADIL or GRCE?

In the previous week, Adial Pharmaceuticals had 2 more articles in the media than Grace Therapeutics. MarketBeat recorded 4 mentions for Adial Pharmaceuticals and 2 mentions for Grace Therapeutics. Grace Therapeutics' average media sentiment score of 1.03 beat Adial Pharmaceuticals' score of 0.00 indicating that Grace Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adial Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Grace Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ADIL or SCYX?

In the previous week, Adial Pharmaceuticals had 1 more articles in the media than SCYNEXIS. MarketBeat recorded 4 mentions for Adial Pharmaceuticals and 3 mentions for SCYNEXIS. SCYNEXIS's average media sentiment score of 0.25 beat Adial Pharmaceuticals' score of 0.00 indicating that SCYNEXIS is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adial Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SCYNEXIS 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer AGFY or ADIL?

Adial Pharmaceuticals has a consensus target price of $15.63, suggesting a potential upside of 286.76%. Given Adial Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Adial Pharmaceuticals is more favorable than Agrify. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Agrify 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Adial Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Does the media refer more to AGFY or ADIL?

In the previous week, Adial Pharmaceuticals had 3 more articles in the media than Agrify. MarketBeat recorded 4 mentions for Adial Pharmaceuticals and 1 mentions for Agrify. Agrify's average media sentiment score of 0.67 beat Adial Pharmaceuticals' score of 0.00 indicating that Agrify is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agrify 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Adial Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ADIL or CLNN?

In the previous week, Adial Pharmaceuticals had 1 more articles in the media than Clene. MarketBeat recorded 4 mentions for Adial Pharmaceuticals and 3 mentions for Clene. Adial Pharmaceuticals' average media sentiment score of 0.00 beat Clene's score of -0.24 indicating that Adial Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adial Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Clene 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Adial Pharmaceuticals (ADIL) Competitors

$4.04 -0.16 (-3.81%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$3.84 -0.20 (-5.05%)

As of 09/23/2026 07:00 PM Eastern

Compare

ADIL vs. RYM, GRCE, SCYX, AGFY, and CLNN

Should you buy Adial Pharmaceuticals stock or one of its competitors? Adial Pharmaceuticals's main competitors and comparable companies include RYTHM (RYM), Grace Therapeutics (GRCE), SCYNEXIS (SCYX), Agrify (AGFY), and Clene (CLNN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Adial Pharmaceuticals compare to RYTHM?

RYTHM (NASDAQ:RYM) and Adial Pharmaceuticals (NASDAQ:ADIL) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and risk.

Adial Pharmaceuticals has a net margin of 0.00% compared to RYTHM's net margin of -6.20%. RYTHM's return on equity of -12.57% beat Adial Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RYTHM	-6.20%	-12.57%	-2.60%
Adial Pharmaceuticals	N/A	-203.87%	-512.41%

Adial Pharmaceuticals has lower revenue, but higher earnings than RYTHM. RYTHM is trading at a lower price-to-earnings ratio than Adial Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RYTHM	$17.28M	2.90	-$33.26M	-$10.53	N/A
Adial Pharmaceuticals	N/A	N/A	-$7.98M	-$14.73	N/A

In the previous week, Adial Pharmaceuticals had 1 more articles in the media than RYTHM. MarketBeat recorded 4 mentions for Adial Pharmaceuticals and 3 mentions for RYTHM. Adial Pharmaceuticals' average media sentiment score of 0.00 beat RYTHM's score of -0.24 indicating that Adial Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RYTHM	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Adial Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Adial Pharmaceuticals has a consensus target price of $15.63, indicating a potential upside of 286.76%. Given Adial Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Adial Pharmaceuticals is more favorable than RYTHM.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RYTHM	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Adial Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

6.0% of RYTHM shares are held by institutional investors. Comparatively, 16.4% of Adial Pharmaceuticals shares are held by institutional investors. 3.5% of RYTHM shares are held by company insiders. Comparatively, 8.0% of Adial Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

RYTHM has a beta of 9.44, indicating that its stock price is 844% more volatile than the broader market. Comparatively, Adial Pharmaceuticals has a beta of 1.38, indicating that its stock price is 38% more volatile than the broader market.

Summary

Adial Pharmaceuticals beats RYTHM on 10 of the 15 factors compared between the two stocks.

How does Adial Pharmaceuticals compare to Grace Therapeutics?

Adial Pharmaceuticals (NASDAQ:ADIL) and Grace Therapeutics (NASDAQ:GRCE) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, dividends, profitability, risk and valuation.

Grace Therapeutics is trading at a lower price-to-earnings ratio than Adial Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adial Pharmaceuticals	N/A	N/A	-$7.98M	-$14.73	N/A
Grace Therapeutics	N/A	N/A	-$7.79M	-$1.18	N/A

Adial Pharmaceuticals has a beta of 1.38, meaning that its share price is 38% more volatile than the broader market. Comparatively, Grace Therapeutics has a beta of 0.44, meaning that its share price is 56% less volatile than the broader market.

Adial Pharmaceuticals presently has a consensus price target of $15.63, indicating a potential upside of 286.76%. Grace Therapeutics has a consensus price target of $6.00, indicating a potential upside of 183.02%. Given Adial Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Adial Pharmaceuticals is more favorable than Grace Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adial Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Grace Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Grace Therapeutics' return on equity of -36.11% beat Adial Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adial Pharmaceuticals	N/A	-203.87%	-512.41%
Grace Therapeutics	N/A	-36.11%	-34.39%

16.4% of Adial Pharmaceuticals shares are held by institutional investors. Comparatively, 6.1% of Grace Therapeutics shares are held by institutional investors. 8.0% of Adial Pharmaceuticals shares are held by insiders. Comparatively, 10.8% of Grace Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Adial Pharmaceuticals had 2 more articles in the media than Grace Therapeutics. MarketBeat recorded 4 mentions for Adial Pharmaceuticals and 2 mentions for Grace Therapeutics. Grace Therapeutics' average media sentiment score of 1.03 beat Adial Pharmaceuticals' score of 0.00 indicating that Grace Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adial Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Grace Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Adial Pharmaceuticals beats Grace Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Adial Pharmaceuticals compare to SCYNEXIS?

Adial Pharmaceuticals (NASDAQ:ADIL) and SCYNEXIS (NASDAQ:SCYX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, earnings and risk.

16.4% of Adial Pharmaceuticals shares are held by institutional investors. Comparatively, 54.4% of SCYNEXIS shares are held by institutional investors. 8.0% of Adial Pharmaceuticals shares are held by insiders. Comparatively, 4.1% of SCYNEXIS shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Adial Pharmaceuticals has a beta of 1.38, meaning that its share price is 38% more volatile than the broader market. Comparatively, SCYNEXIS has a beta of 1.11, meaning that its share price is 11% more volatile than the broader market.

Adial Pharmaceuticals currently has a consensus price target of $15.63, indicating a potential upside of 286.76%. SCYNEXIS has a consensus price target of $33.00, indicating a potential upside of 611.21%. Given SCYNEXIS's higher possible upside, analysts clearly believe SCYNEXIS is more favorable than Adial Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adial Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
SCYNEXIS	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Adial Pharmaceuticals has a net margin of 0.00% compared to SCYNEXIS's net margin of -41.79%. SCYNEXIS's return on equity of -44.15% beat Adial Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adial Pharmaceuticals	N/A	-203.87%	-512.41%
SCYNEXIS	-41.79%	-44.15%	-32.61%

In the previous week, Adial Pharmaceuticals had 1 more articles in the media than SCYNEXIS. MarketBeat recorded 4 mentions for Adial Pharmaceuticals and 3 mentions for SCYNEXIS. SCYNEXIS's average media sentiment score of 0.25 beat Adial Pharmaceuticals' score of 0.00 indicating that SCYNEXIS is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adial Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
SCYNEXIS	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Adial Pharmaceuticals has higher earnings, but lower revenue than SCYNEXIS. SCYNEXIS is trading at a lower price-to-earnings ratio than Adial Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adial Pharmaceuticals	N/A	N/A	-$7.98M	-$14.73	N/A
SCYNEXIS	$20.60M	2.24	-$8.61M	-$2.09	N/A

Summary

Adial Pharmaceuticals beats SCYNEXIS on 8 of the 15 factors compared between the two stocks.

How does Adial Pharmaceuticals compare to Agrify?

Agrify (NASDAQ:AGFY) and Adial Pharmaceuticals (NASDAQ:ADIL) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and media sentiment.

Adial Pharmaceuticals has a net margin of 0.00% compared to Agrify's net margin of -424.11%. Agrify's return on equity of -185.90% beat Adial Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agrify	-424.11%	-185.90%	-72.67%
Adial Pharmaceuticals	N/A	-203.87%	-512.41%

Agrify has a beta of 9.96, suggesting that its share price is 896% more volatile than the broader market. Comparatively, Adial Pharmaceuticals has a beta of 1.38, suggesting that its share price is 38% more volatile than the broader market.

Adial Pharmaceuticals has a consensus target price of $15.63, suggesting a potential upside of 286.76%. Given Adial Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Adial Pharmaceuticals is more favorable than Agrify.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agrify	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Adial Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Adial Pharmaceuticals has lower revenue, but higher earnings than Agrify. Agrify is trading at a lower price-to-earnings ratio than Adial Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agrify	$12.26M	3.83	-$41.75M	-$22.65	N/A
Adial Pharmaceuticals	N/A	N/A	-$7.98M	-$14.73	N/A

In the previous week, Adial Pharmaceuticals had 3 more articles in the media than Agrify. MarketBeat recorded 4 mentions for Adial Pharmaceuticals and 1 mentions for Agrify. Agrify's average media sentiment score of 0.67 beat Adial Pharmaceuticals' score of 0.00 indicating that Agrify is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agrify	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Adial Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

6.0% of Agrify shares are owned by institutional investors. Comparatively, 16.4% of Adial Pharmaceuticals shares are owned by institutional investors. 2.2% of Agrify shares are owned by insiders. Comparatively, 8.0% of Adial Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Adial Pharmaceuticals beats Agrify on 10 of the 15 factors compared between the two stocks.

How does Adial Pharmaceuticals compare to Clene?

Adial Pharmaceuticals (NASDAQ:ADIL) and Clene (NASDAQ:CLNN) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, media sentiment, profitability, dividends, risk and institutional ownership.

Adial Pharmaceuticals has a net margin of 0.00% compared to Clene's net margin of -20,063.96%. Clene's return on equity of 0.00% beat Adial Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adial Pharmaceuticals	N/A	-203.87%	-512.41%
Clene	-20,063.96%	N/A	-137.04%

16.4% of Adial Pharmaceuticals shares are held by institutional investors. Comparatively, 23.3% of Clene shares are held by institutional investors. 8.0% of Adial Pharmaceuticals shares are held by insiders. Comparatively, 28.3% of Clene shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Adial Pharmaceuticals currently has a consensus target price of $15.63, suggesting a potential upside of 286.76%. Clene has a consensus target price of $34.00, suggesting a potential upside of 692.54%. Given Clene's stronger consensus rating and higher probable upside, analysts clearly believe Clene is more favorable than Adial Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adial Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Clene	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Adial Pharmaceuticals has higher earnings, but lower revenue than Clene. Clene is trading at a lower price-to-earnings ratio than Adial Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adial Pharmaceuticals	N/A	N/A	-$7.98M	-$14.73	N/A
Clene	$197K	282.97	-$26.17M	-$3.50	N/A

In the previous week, Adial Pharmaceuticals had 1 more articles in the media than Clene. MarketBeat recorded 4 mentions for Adial Pharmaceuticals and 3 mentions for Clene. Adial Pharmaceuticals' average media sentiment score of 0.00 beat Clene's score of -0.24 indicating that Adial Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adial Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Clene	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Adial Pharmaceuticals has a beta of 1.38, suggesting that its share price is 38% more volatile than the broader market. Comparatively, Clene has a beta of 0.95, suggesting that its share price is 5% less volatile than the broader market.

Summary

Clene beats Adial Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

Get Adial Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADIL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ADIL vs. The Competition

Export

Metric	Adial Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$11.03M	$12.60B	$7.31B	$13.29B
Dividend Yield	N/A	2.63%	2.52%	12.57%
P/E Ratio	-0.27	792.28	274.08	25.69
Price / Sales	N/A	862.22	638.21	78.99
Price / Cash	N/A	88.64	77.80	52.76
Price / Book	0.85	10.59	10.47	6.32
Net Income	-$7.98M	$2.81B	$3.49B	$359.73M
7 Day Performance	-22.46%	-0.11%	-0.67%	0.17%
1 Month Performance	-25.19%	-1.34%	-3.17%	-3.27%
1 Year Performance	-53.52%	2.86%	15.14%	5.58%

Adial Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ADIL Adial Pharmaceuticals	2.6074 of 5 stars	$4.04 -3.8%	$15.63 +286.8%	-53.0%	$11.03M	N/A	N/A	6	News Coverage
RYM RYTHM	0.6329 of 5 stars	$22.49 -2.9%	N/A	-39.2%	$49.02M	$17.28M	N/A	140	News Coverage
GRCE Grace Therapeutics	2.0433 of 5 stars	$2.32 +2.7%	$6.00 +158.6%	-31.8%	$48.60M	N/A	N/A	N/A
SCYX SCYNEXIS	2.7866 of 5 stars	$4.88 +3.8%	$33.00 +576.4%	-45.8%	$48.55M	$20.60M	N/A	60
AGFY Agrify	N/A	$23.16 -2.0%	N/A	-40.4%	$46.39M	$12.26M	N/A	140	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ADIL) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Adial Pharmaceuticals (ADIL) Competitors

ADIL vs. RYM, GRCE, SCYX, AGFY, and CLNN

How does Adial Pharmaceuticals compare to RYTHM?

Summary

How does Adial Pharmaceuticals compare to Grace Therapeutics?

Summary

How does Adial Pharmaceuticals compare to SCYNEXIS?

Summary

How does Adial Pharmaceuticals compare to Agrify?

Summary

How does Adial Pharmaceuticals compare to Clene?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADIL vs. The Competition

Adial Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Adial Pharmaceuticals (ADIL) Competitors

ADIL vs. RYM, GRCE, SCYX, AGFY, and CLNN

How does Adial Pharmaceuticals compare to RYTHM?

Is RYM or ADIL more profitable?

Which has preferable valuation and earnings, RYM or ADIL?

Does the media prefer RYM or ADIL?

Do analysts rate RYM or ADIL?

Do institutionals & insiders have more ownership in RYM or ADIL?

Which has more risk and volatility, RYM or ADIL?

Summary

How does Adial Pharmaceuticals compare to Grace Therapeutics?

Which has preferable earnings and valuation, ADIL or GRCE?

Which has more risk & volatility, ADIL or GRCE?

Do analysts prefer ADIL or GRCE?

Is ADIL or GRCE more profitable?

Do institutionals & insiders believe in ADIL or GRCE?

Does the media refer more to ADIL or GRCE?

Summary

How does Adial Pharmaceuticals compare to SCYNEXIS?

Do institutionals and insiders believe in ADIL or SCYX?

Which has more volatility and risk, ADIL or SCYX?

Do analysts recommend ADIL or SCYX?

Is ADIL or SCYX more profitable?

Does the media prefer ADIL or SCYX?

Which has stronger valuation & earnings, ADIL or SCYX?

Summary

How does Adial Pharmaceuticals compare to Agrify?

Is AGFY or ADIL more profitable?

Which has more risk & volatility, AGFY or ADIL?

Do analysts prefer AGFY or ADIL?

Which has preferable valuation & earnings, AGFY or ADIL?

Does the media refer more to AGFY or ADIL?

Do institutionals and insiders hold more shares of AGFY or ADIL?

Summary

How does Adial Pharmaceuticals compare to Clene?

Is ADIL or CLNN more profitable?

Do insiders & institutionals hold more shares of ADIL or CLNN?

Do analysts rate ADIL or CLNN?

Which has preferable valuation and earnings, ADIL or CLNN?

Does the media refer more to ADIL or CLNN?

Which has more risk & volatility, ADIL or CLNN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADIL vs. The Competition

Adial Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools